A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG

Enrolling by invitation

Conditions studied: Prostate Cancer, Breast Cancer, Neuroendocrine Tumors

In brief

The purpose of this research study is to test new ways to improve the usefulness of the world's first total-body positron emission tomography (PET)/computed tomography (CT) scanner (EXPLORER) by collecting data from PET scans using one of three different imaging agents: 18F-PSMA; 18F-FES; or, 68Ga DOTATATE. These imaging agents are approved by the FDA to be used for patients diagnosed with prostate cancer (18F-PSMA), neuroendocrine tumor (68Ga DOTATATE), or breast cancer (18F-FES).

Key facts

Study ID
NCT05160480
Run by
University of California, Davis
People needed
9
Starts
2024-06-07
Expected to finish
2026-09-01
Last updated by the study team
2026-03-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.